Sanofi reserves up to $2.7B a year for bolt-ons; Alnylam earns $7M milestone from Genzyme;

@FierceBiotech: Welcome Galen Moore, the new managing editor of FierceBiotechFiercePharma and FierceMedicalDevices! | Follow @FierceBiotech

@JohnCFierce: Whoa, FDA gets mighty cross with 23andMe, tackles Anne Wojcicki. Want to see what angry regulators look like? FDA warning letter | Follow @JohnCFierce

@DamianFierce: With $43M in the bank, startup Editas sets off in pioneering "molecular surgery" field. News | Follow @DamianFierce

@EmilyMFierce: Biota scraps preclinical antibiotics program as antimicrobial resistance grows. Story | Follow @EmilyMFierce

> Faced with falling sales, Sanofi ($SNY) CEO Chris Viehbacher has vowed to invest up to about $2.7 billion a year in new acquisitions. Top fields of interest: diabetes, vaccines, animal health and rare disease. Story

> Cambridge, MA-based Alnylam ($ALNY) is picking up a $7 million milestone from Genzyme for its work on the ATTR drug patisiran. Story

> Progenics ($PGNX) says it will resume a Phase IIb study of Azedra, a rare endocrine tumor drug. Release

Medical Device News

@FierceMedDev: A French start-up nailed some major financing for its retinal implant - a $20M-plus Series A. Story | Follow @FierceMedDev

@MarkHFierce: TB Dx maker Oxford Immunotec launched a relatively-modest IPO but it gained steam in initial trading. Friday's story | Follow @MarkHFierce

> Under Icahn's pressure, Hologic's M&A prospects heat up. Story

> Key piece of Roche, Novo Nordisk diabetes device deal nears EU approval. Article

> Sorin CE nails CE mark for extra-large size of sutureless aortic valve. Item

Pharma News

@FiercePharma: The weekend's best-read special report: Top 10 Pharma Companies by 2012 Revenue. Report | Follow @FiercePharma

@EricPFierce: FDA approves, buys GSK vaccine in case of H1N1 pandemic. More | Follow @EricPFierce

@CarlyHFierce: Voters in Switzerland turn down strict CEO pay limits. Story | Follow @CarlyHFierce

> 2014 deal outlook: Sanofi eyes $2.7B in buys; AZ analysts figure on bigger M&A. Report

> Who leaked the scary Copaxone numbers? Teva aims to find out. Story

> J&J's newly approved Olysio to rival Merck and Vertex entries in hep C market. Item

CRO News

> Indian CROs leap into U.S. with joint venture. News

> Pharmacyclics, J&J pick Catalent for blockbuster cancer drug. More

> ResearchDx reaches into India for contract diagnostics work. News

> Covance taps NeoGenomics for cancer trial diagnostics. Article

> Vietnam taps Quintiles to up its stake in global trials. Story

Biotech IT News

> Google begins hiring team to lead Calico. More

> Life sciences IT execs plan business intelligence spending blitz. News

> Lilly, Novartis and Pfizer sign up to improve Story

> Report finds inexcusable failings in government cybersecurity. Piece

> Novartis looks to data management vendors to slash costs. Article

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.